Search

Displaying results 4191 - 4200 of 5897 in total
  1. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  2. Drug

    VB-201

    go.drugbank.com/drugs/DB15259
    Investigational

    VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).

  3. Drug

    OptPA

    go.drugbank.com/drugs/DB18325
    Experimental

    Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.[A261486]

  4. Drug

    Guanosine-5'-Triphosphate

    go.drugbank.com/drugs/DB04137
    Experimental

    A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. [PubChem]

  5. Drug

    Cytidine-5'-Triphosphate

    go.drugbank.com/drugs/DB02431
    Experimental

    A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety. [PubChem]

  6. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. … It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.

  7. Drug

    ADU-S100

    go.drugbank.com/drugs/DB14722
    Investigational

    ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system. … ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression of cytokines and chemokines, leading to a robust and durable antigen-specific T-cell mediated immune

  8. Drug

    Zanidatamab zovodotin

    go.drugbank.com/drugs/DB15472
    Experimental

    According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload." … [L8234] It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies

  9. Drug

    Tretamine

    go.drugbank.com/drugs/DB14031
    Experimental

    Toxic alkylating agent used in industry; also as antineoplastic and research tool to produce chromosome aberrations and cancers.

  10. Drug

    Agerafenib

    go.drugbank.com/drugs/DB15068
    Investigational

    Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).